Next Article in Journal
The Measurement of Elderly Volunteers’ Optic Nerve Sheath Diameters by Ocular Ultrasonography
Previous Article in Journal
Modeling the Angle-Specific Isokinetic Hamstring to Quadriceps Ratio Using Multilevel Generalized Additive Models
Open AccessReview

Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches

1
Department of Morphological Sciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca 400012, Romania
2
Department of Pathology, IMOGEN Research Centre, Cluj-Napoca 400012, Romania
3
Department of Pharmaceutical Analysis, Faculty of Pharmacy, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca 400012, Romania
4
Department of Proteomics and Metabolomics, MedFuture Research Center for Advanced Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca 400012, Romania
5
Department of Neurosurgery, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca 400012, Romania
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(8), 412; https://doi.org/10.3390/medicina55080412
Received: 27 May 2019 / Revised: 22 July 2019 / Accepted: 24 July 2019 / Published: 27 July 2019
  |  
PDF [318 KB, uploaded 27 July 2019]
  |  

Abstract

Being the fourth leading cause of cancer-related death, glial tumors are highly diverse tumor entities characterized by important heterogeneity regarding tumor malignancy and prognosis. However, despite the identification of important alterations in the genome of the glial tumors, there remains a gap in understanding the mechanisms involved in glioma malignancy. Previous research focused on decoding the genomic alterations in these tumors, but due to intricate cellular mechanisms, the genomic findings do not correlate with the functional proteins expressed at the cellular level. The development of mass spectrometry (MS) based proteomics allowed researchers to study proteins expressed at the cellular level or in serum that may provide new insights on the proteins involved in the proliferation, invasiveness, metastasis and resistance to therapy in glial tumors. The integration of data provided by genomic and proteomic approaches into clinical practice could allow for the identification of new predictive, diagnostic and prognostic biomarkers that will improve the clinical management of patients with glial tumors. This paper aims to provide an updated review of the recent proteomic findings, possible clinical applications, and future research perspectives in diffuse astrocytic and oligodendroglial tumors, pilocytic astrocytomas, and ependymomas. View Full-Text
Keywords: diffuse glioma; glioblastoma; proteomics; mass spectrometry; biomarker diffuse glioma; glioblastoma; proteomics; mass spectrometry; biomarker
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pirlog, R.; Susman, S.; Iuga, C.A.; Florian, S.I. Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches. Medicina 2019, 55, 412.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top